Gan Shmuel 2025: Prices Fell, the Far East Softened, and Thailand Still Needs Proof

Company Introduction

What matters about Gan Shmuel is that it is not really a local juice producer story. At its core this is an ingredients platform for the food and beverage industry, with an export-heavy industrial engine and a smaller retail layer built around Primor and Meitav. In 2025 the company generated $261.5 million of revenue, about 77% of it from exports, and the industrial segment alone accounted for $214.1 million. On a first read that can look like a simple normalization year after an unusually strong 2024.

That reading is too flat. What worked in 2025 is not what worked in 2024. Retail stayed relatively stable, the balance sheet remained strong, and there is no covenant pressure forcing the company to stop. What weakened is exactly the industrial layer that drove the peak year: global concentrate prices fell sharply, the Far East cooled, and industrial operating profit was cut by more than half.

That is why the full-year number on its own can mislead. Gan Shmuel still finished 2025 with $16.1 million of net profit, but by the fourth quarter it had already slipped to a $2.0 million net loss and just $0.4 million of operating profit. So the question for 2026 is no longer whether the company knows how to make money. It is whether the late-2025 profit level was only a temporary trough, or whether the industrial engine needs a deeper reset.

The second superficial mistake would be to assume that the Thailand plant automatically fixes the problem. It does not. The Thailand facility was built as a concentrates-and-bases plant, not as a fruit-processing plant. Over time it may shorten the route to Asian customers and strengthen the tailor-made layer, but by itself it does not solve the raw-material question and it does not create immediate demand. In 2025 it was still mainly capex, payroll and setup. The commercial proof should only start to appear after the ramp-up that was completed in the first quarter of 2026.

That is why 2026 looks like a proof year, not a celebration year. If the industrial engine stabilizes without needing the extreme 2024 pricing backdrop, if the Primor distribution transition moves through two new distributors without hurting shelf presence, and if Thailand starts turning from a ready plant into actual sales, the picture can get cleaner. If not, investors may find that 2025 was not just a price reset, but also an early warning on the company’s exit rate.

The Economic Map

Three points emerge from that map. First, Gan Shmuel is still overwhelmingly an industrial story. Second, the 2025 decline did not come from a weak Israeli market but mainly from Asia cooling. Third, retail provides some stability, but it is far too small to offset a deep disruption in the industrial engine.

Events And Triggers

2025 was not about one isolated event. It was a year in which several material processes moved together, each changing a different layer of the story.

The first trigger: the concentrate market reversed. After the exceptional price run of 2023 and 2024, 2025 saw a sharp decline in global orange-concentrate prices. The company itself attributes that to a better Brazilian crop and weaker demand. What matters is how that flowed through the numbers: group revenue fell by $46.8 million, but the Far East alone was down $55.8 million. So this was not just a price issue. It was also an ordering pace and geographic-mix issue.

The second trigger: Thailand moved from construction into ramp-up. The plant structure was completed in the first quarter of 2025, the equipment and production lines were installed and tested in the second and third quarters, and on November 19, 2025 the company received a formal food-manufacturing license from the Thai FDA. That is an important outside signal, because it means the project moved beyond buildout and into a stage where activity can actually be loaded onto it. But the 2025 annual report still does not show proof of meaningful sales from the site. For now, Thailand is a real operational option, not a proven profit engine.

The third trigger: retail entered a distribution transition year. Until the end of 2025 Strauss was a major customer distributing Primor’s chilled products, and revenue from Strauss represented about 58% of retail-segment revenue. At the same time, Sugat started distributing nectars and soft drinks in February 2025, and from January 2026 Osem took over chilled-juice distribution. That means Primor entered 2026 facing not only a demand question but also an execution question. The transition can improve reach and focus, but it also adds friction in a category that is not easy.

The fourth trigger: the company maintained a generous distribution pace even in a normalization year. In March 2025 it approved a NIS 40 million dividend, and in January 2026 it approved another NIS 30 million. In the investor presentation the company highlighted NIS 70 million of total distributions from the start of 2025 through the report date. This is not a sign of stress. If anything, it suggests management believes the balance sheet can carry the transition period. The market will have to test whether that remains true without a quick recovery in the industrial engine.

Efficiency, Profitability And Competition

The central insight is that the 2025 damage was much sharper in earnings quality than in revenue. Sales fell 15.2%, but gross profit fell 34.0% and operating profit 56.4%. That is a classic sign that the blow was not only volume. It was also price and mix.

The Reset Is Industrial, Not Retail

The industrial segment fell from $259.6 million of revenue to $214.1 million, while its operating profit dropped from $56.4 million to $24.5 million. By contrast, the retail segment hardly moved on revenue, and its gross profit stayed around $12.9 million. In other words, 2025 was not a collapse of the whole company. It was a break in the unusually strong profit layer the industrial engine produced in 2024.

That matters because it prevents the wrong read. If the entire group had weakened at the same intensity, the conclusion would be a broad demand problem. That is not what the numbers say. Retail held up, Israel was almost flat, and the real weakness sat exactly in the segment most exposed to concentrate pricing and export ordering.

There is another useful detail inside the industrial segment. Revenue from fruit products fell from $253.2 million to $205.6 million, but fruit by-products actually rose from $4.4 million to $6.5 million. That suggests the company still knows how to extract value from the broader industrial platform and is not merely a simple commodity processor. In 2025, however, that was nowhere near enough to offset the scale of the concentrate-price reset and the drop in purchasing intensity.

The Real Problem Is The Exit Rate

The full-year figure still looks respectable. The problem is the edge. In the first quarter of 2025 operating profit was $12.2 million. In the second quarter it fell to $5.5 million, in the third quarter it was $6.9 million, and in the fourth quarter it almost disappeared at just $0.4 million. Gross margin in the fourth quarter fell to 17.9% of sales, versus 28.5% in the comparable quarter.

That point matters because it changes how 2026 should be read. Anyone looking only at the full year sees a company that still generated $25 million of operating profit. Anyone looking at the fourth quarter sees a company entering 2026 from a much lower base. Markets tend to focus on the exit rate, not just the annual average.

The Advantages Are Real, But There Is No Backlog To Lean On

Gan Shmuel does have real operating advantages: the combination of fruit processing and customer-specific products, the ability to monetize by-products, sales into roughly 50 countries, a customs advantage on part of its exports into Europe, and no single industrial customer above 10% of revenue. Those are platform advantages, not one-customer advantages.

But there is also an important limitation: the company does not have backlog in the usual sense. Sales are made through current orders and non-binding customer forecasts. That means management cannot hide behind a nice backlog line. If prices, demand, or Asian distribution remain soft, that will show up quickly in reported sales.

That is also the difference between Thailand as a strategy and Thailand as proof. A concentrates-and-bases plant in Thailand may be a smart move if it shortens response time to customers, improves local market fit, and creates a new Asian operating base. But it does not come with an order book that guarantees the outcome. In 2026 the company still has to show actual orders.

Cash Flow, Debt And Capital Structure

Precision matters here, because 2025 can be told in two very different ways.

Frame One: The Existing Business Still Generates Cash

If the lens is operating cash flow alone, Gan Shmuel still produced $24.7 million of positive cash flow in 2025. That was down from $42.2 million in 2024, but it is still a respectable level for a company with $261.5 million of revenue. Trade receivables also fell by $8.6 million, helping offset part of the earnings hit.

There was friction, though. Inventory rose by $6.7 million, and the inventory mix became heavier in raw materials: raw materials increased from $32.9 million to $42.5 million, while finished goods and purchased goods fell from $32.2 million to $29.1 million. That suggests the company chose to hold more raw materials during a year of falling prices and softer demand. Cash taxes paid also jumped to $9.9 million.

So the business still generates cash, but not as effortlessly as before. And because the company does not disclose maintenance capex separately, there is no clean way to convert the $24.7 million of operating cash flow into a hard “normalized free cash flow” number. The safe conclusion is narrower: the existing business still generates cash before the larger capital uses.

Frame Two: All-In Cash Flexibility

If the lens is total real cash use, the picture is more conservative. In 2025 the company invested $9.0 million in property, plant and equipment, another $2.9 million in an associate, paid $4.5 million of lease liabilities, repaid $2.0 million of long-term debt, and paid $10.2 million of dividends. That is why, despite positive operating cash flow, cash still fell by $2.4 million to $17.3 million.

That is exactly where the balance sheet buys time. Cash and cash equivalents stood at $17.3 million, short-term investments at $2.9 million, and bank debt at just $4.3 million short term plus $0.8 million long term. Equity stood at $176.1 million, or 73% of the balance sheet, while the main bank covenant requires tangible equity of only 25%. In plain terms, Gan Shmuel is far from a financing squeeze. It is simply choosing to carry three uses of capital at the same time: dividends, Thailand investment, and ongoing operations.

There is another layer worth surfacing. Below operating profit, the company recorded a $6.8 million fair-value expense in 2025 from the TransAlgae investment, versus $4.3 million in 2024. That is not an operating expense, but it did drag profit before tax down from $25.0 million of operating profit to $16.9 million before tax. Anyone looking only at the bottom line can easily mix up operating pressure with investment drag.

Debt, Covenants And FX

The debt itself is not alarming. The company carries modest bank debt in dollars at fixed rates of 3.85% to 4.98%, and it easily complies with its financial covenants. FX exposure matters more. At year end 2025 the company had a net excess of shekel liabilities over financial assets relative to the dollar of $31.6 million, and management says about 75% of the currency exposure is hedged. Its own sensitivity analysis shows that a 10% move in the shekel-dollar rate changes profit before tax by roughly $3.16 million.

That means the main balance-sheet friction is not banking risk. It is the mix of currency, working capital and capital-allocation decisions. As long as industrial profitability recovers, that remains manageable. If profitability stays near the fourth-quarter level, every capital use starts to feel heavier.

Outlook

Before turning to 2026, five findings need to be fixed clearly in place.

• First finding: the exit rate was much weaker than the full year. $25 million of operating profit for the year hides an almost flat fourth quarter.
• Second finding: the decline in the Far East was larger than the group’s total revenue decline. Europe offset part of the fall, but not enough to change the story.
• Third finding: retail did not break. The problem in 2025 was not broad domestic demand. It was mainly a reset in industrial export profitability.
• Fourth finding: Thailand advanced operationally, but in 2025 still did not provide revenue proof. This is a project with a license, equipment and ramp-up, not yet with demonstrated operating contribution.
• Fifth finding: there is no backlog. So there is no “pipeline” line to lean on. Proof will come only through reported sales in the coming quarters.

Taken together, those five points lead to a fairly clean conclusion: 2026 is a proof year for the industrial engine, not another peak-profit year. The company does not need a return to 2024 concentrate prices to look better. It does need to show that the industrial segment can earn at a more stable level even in a lower-price environment, and that the fourth-quarter drop was not the new base.

The first condition is stabilization in pricing and order flow. The company itself describes a market in which customers slowed purchases and waited for pricing to settle. So the right way to read the next reports is not only through sales, but through whether gross margin rises off the late-2025 trough.

The second condition is execution of the new retail-distribution layer. In 2025 Strauss represented 58% of retail-segment revenue. The shift to Sugat and Osem may create better reach, but it has to happen without hurting a category in which the company’s share of the chilled natural-fresh-juice market in Israel fell to 47.9% in 2025, from 52.9% in 2024 and 55.4% in 2023. That is not a disaster, but it is a reminder that even the company’s strongest domestic brand is not sitting in a competition-free category.

The third condition is Thailand. Here the right stance is pragmatic. The project is no longer a slide. The structure is complete, the lines were installed, the food-manufacturing license has been granted, and the workforce reached 12. Now investors need to see whether the plant actually starts contributing to production, marketing and distribution in Asia. Without that, Thailand remains another layer of overhead, payroll and capex.

The fourth condition is capital discipline. The company can afford dividends even after a normalization year, but if 2026 does not show a sufficient recovery in the industrial engine, it will become harder to justify distributions, investment and ongoing inventory build at the same time. There is no funding pressure today. There is a capital-allocation test.

Risks

The biggest risk at Gan Shmuel is not a survival risk. It is a misread risk. A company with 73% equity, low bank debt and positive operating cash flow does not look like trouble. But such a company can still spend several quarters stuck if the industrial engine exits the year at a low profit level while the new projects are not yet mature.

Pricing And Demand Risk In The Industrial Segment

The company operates in a world where concentrate prices, fruit availability and juice-category demand can change quickly. 2025 showed how directly that hits profitability. The fact that there is no backlog makes the risk sharper, because there is no long-duration contract layer smoothing the blow.

Retail Distribution-Transition Risk

The shift away from Strauss and into Osem, alongside Sugat’s role in nectars and soft drinks, can work well. But it also introduces execution risk in a business that depends on brand strength, shelf visibility and retail service. If there is friction, it will hit a category competing against Prigat, Yafora, Tempo, Priniv and private-label brands.

Capital-Allocation Risk

A strong balance sheet does not change the fact that capital is being sent simultaneously to dividends, Thailand, an associate investment and a financial investment that is still being marked down. That does not mean the policy is wrong. It does mean the next year needs to start producing something more tangible from past investment.

Ownership-Structure And Operating-Ecosystem Risk

Gan Shmuel operates inside a dense ecosystem of controlling-shareholder and related-party arrangements: land rent, manpower, general services, fruit purchases and officer-services agreements. This is not a new risk, and it is not hidden. But it does mean part of the cost base and part of the operating flexibility run through ongoing agreements with the kibbutz and related kibbutzim, not only through open external markets.

Conclusions

Gan Shmuel did not come out of 2025 as a broken company. It came out as a company that clearly understands its industry, still earns money, and still carries a strong balance sheet, but also as a company whose 2024 earnings were much more a function of exceptional market conditions than of structural immunity. That is what supports the thesis today: stable retail, financial balance, FX hedging, and real progress in Thailand. That is what blocks it: a very weak exit rate, a cooler Asian market, and no commercial proof yet from the new project.

In the short to medium term the market is likely to watch three things. First, whether the fourth quarter was only a temporary bottom. Second, whether Primor gets through the distribution shift cleanly. Third, whether Thailand starts appearing as a real operating engine rather than only as an investment line.

Current thesis: Gan Shmuel remains a high-quality and conservatively financed business, but 2025 showed that the exceptional 2024 profit level was driven much more by pricing and geography than by a moat that is immune to the cycle.

What changed versus the previous read: it is now much clearer that the issue is not whether the company knows how to produce, but whether it can preserve good industrial profitability when global pricing falls and the Far East weakens.

The strongest counter-thesis: 2025 may simply have been an unusually sharp transition year between peak pricing and normalization, and once customers finish destocking and Thailand starts commercial activity, profitability may recover to a good level without any structural change.

What could change the market’s interpretation over the short to medium term: a string of quarters with a steadier gross margin, proof that the move to Osem did not hurt retail, or, on the other side, another weak quarter that confirms the fourth quarter was not an outlier.

Why this matters: Gan Shmuel is not a survival story. It is an earnings-quality story. The difference between a good company and a truly strong export platform here comes down to whether it can keep earning well outside exceptional peak years.

What must happen over the next 2 to 4 quarters: the industrial engine has to stabilize, Thailand has to show a first commercial contribution, and retail has to get through the distribution shift without losing share and operating quality.